BIO-TECHNE Corp Operating Lease Right-of-Use Assets
BIO-TECHNE Corp (TECH) had Operating Lease Right-of-Use Assets of $67.33 million as of 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-24
- 2026-06-30: Operating Lease, Right-of-Use Asset $67.33M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $68.32M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $68.25M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $70.72M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $67.33M 10-K · filed 2026-08-24 |
| 2026-03-31 | $68.32M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $68.25M 10-Q · filed 2026-02-04 |
| 2025-09-30 | $70.72M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $73.40M 10-K · filed 2026-08-24 |
| 2025-03-31 | $83.74M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $85.38M 10-Q · filed 2025-02-06 |
| 2024-09-30 | $89.22M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $91.28M 10-K · filed 2025-08-22 |
| 2024-03-31 | $97.26M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $100.86M 10-Q · filed 2024-02-07 |
| 2023-09-30 | $102.28M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $98.33M 10-K · filed 2024-08-22 |
| 2023-03-31 | $97.98M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $83.94M 10-Q · filed 2023-02-07 |
| 2022-09-30 | $69.75M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $65.56M 10-K · filed 2023-08-23 |
| 2022-03-31 | $63.45M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $64.29M 10-Q · filed 2022-02-07 |
| 2021-09-30 | $71.40M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $73.83M 10-K · filed 2022-08-24 |
| 2021-03-31 | $71.83M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $68.15M 10-Q · filed 2021-02-08 |
| 2020-09-30 | $70.02M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $71.47M 10-K · filed 2021-08-25 |
| 2020-03-31 | $73.75M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $75.82M 10-Q · filed 2020-02-06 |
| 2019-09-30 | $76.96M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $0.00 10-K · filed 2020-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |